Literature DB >> 8217594

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

T Philip1, S Negrier, C Lasset, B Coronel, M Bret, J Y Blay, Y Merrouche, C Carrie, P Kaemmerlen, F Chauvin.   

Abstract

This study was performed with the aim of discovering the characteristics and survival of patients with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen. One hundred and eighty-one patients with metastatic renal carcinoma were referred to our institute from October 1987 until August 1991; 129 were treated with Interleukin 2 with or without Interferon alpha in three successive protocols. Fifty-two patients were not treated with immunotherapy due to the exclusion criteria of the protocols. Sixty-four patients with the same disease who had been referred to our institute before the initiation of this programme (1982, 1987) were also analysed as a control group. The main characteristics of the three different cohorts of patients were analysed and compared with univariate statistical tests; the median survival of the patients was calculated and compared. The referral rate increased from 13 a year to 45 a year while the IL2 trials were being conducted. Patients treated with cytokines have a median survival of 18 months after occurrence of metastases, compared to 6 and 8 months, respectively, in excluded patients and the control group. This parameter is of 15 months when the 181 patients, treated with cytokines or not, are considered. The survival of treated vs excluded patients is significantly different (P < 10(-6); so is the survival of the 181 patients recently included when compared to the historical group (P:10(-5). When the 181 recent patients are compared to the historical control group, a number of differences appear in their characteristics, which prevent us from drawing any conclusion about the role of immunotherapy in the improvement of survival observed. This study clearly evidences the selection of the patients receiving immunotherapy and the modification in referrals of a disease induced by a new available therapy. This emphasises the need for prospective studies in this setting.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217594      PMCID: PMC1968726          DOI: 10.1038/bjc.1993.476

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

Review 1.  Interferon treatment of renal cell carcinoma. Current status and future prospects.

Authors:  S E Krown
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

2.  Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.

Authors:  J P Droz; C Theodore; M Ghosn; H Lupera; G Piot; A De Forges; M Klink; J Rouesse; J L Amiel
Journal:  Semin Surg Oncol       Date:  1988

3.  On lymphokines, cytokines, and breakthroughs.

Authors:  C G Moertel
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

Review 4.  The natural history and clinical features of renal carcinoma.

Authors:  A W Ritchie; J B deKernion
Journal:  Semin Nephrol       Date:  1987-06       Impact factor: 5.299

5.  Prognostic factors in metastatic renal carcinoma.

Authors:  J D Maldazys; J B deKernion
Journal:  J Urol       Date:  1986-08       Impact factor: 7.450

6.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

7.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Renal cell carcinoma: antitumor effects of leukocyte interferon.

Authors:  J R Quesada; D A Swanson; A Trindade; J U Gutterman
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

9.  Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

Authors:  P A Palmer; J Vinke; T Philip; S Negrier; J Atzpodien; H Kirchner; R Oskam; C R Franks
Journal:  Ann Oncol       Date:  1992-06       Impact factor: 32.976

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.

Authors:  R Henriksson; S Nilsson; S Colleen; P Wersäll; M Helsing; R Zimmerman; K Engman
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

2.  Hereditary factors in basal cell carcinoma of the skin: a population-based cohort study in twins.

Authors:  V Bataille; H Snieder; A MacGregor; T Spector
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.